glp-1 and diabetes GLP-1-based therapies for type 2 diabetes: from single, dual triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1a: Going beyond Traditional Use

Whether part of a targeted treatment plan or general wellness support, they offer a versatile tool in functional and aesthetic medicine

I have been long LLY and NVO because of GLP-1 drugs since early 2022, but as evidence continues to amass in favour of their utility for a large population its worth considering - what other implications does this have

The extension of the max peaks wavelengths within the displayed absorbance spectra towards the near infrared region is exaggerated as the APTES concentration is increased from 0.1 to 0.16% APTES

Wikipedia (2026) 8

(2022) demonstrated Cerebrolysin's effects on Alzheimer's disease biomarkers in a randomized controlled trial, providing objective biological evidence for its neurotrophic activity (PMID: 36155516) Regulatory Validation: Approved for clinical use in over 40 countries for indications including stroke, traumatic brain injury, and dementia (though not FDA-approved in the United States) Dihexa: Preclinical Only, with Integrity Concerns Dihexa's evidence base is entirely preclinical and has faced significant scientific integrity challenges: Foundational Research: Wright et al